Metin Çelik, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Metin Çelik, PhD


Metin Çelik, PhD
President, Pharmaceutical
Technologies
International (PTI)

Metin Çelik is the founder and president of Pharmaceutical Technologies International, Inc., and is also a pharmaceutical processing research professor in the Department of Industrial Engineering at Rutgers University. Prior to that, he was a faculty member at Rutgers’ College of Pharmacy. Çelik received his BSc (Hons.) degree in pharmacy from Hacettepe University-Turkey and was awarded a PhD degree in Pharmaceutical Technology from Leicester Polytechnic-UK. Çelik worked at Sandoz-Switzerland and Sandoz-Turkey before he joined Smith Kline & French Laboratories to establish the first state-of-the-art compaction simulator system in the western hemisphere. He developed the second unit at Rutgers as the first such a unit in academia in the US and established an internationally recognized research center.

Çelik has organized more than 40 national and international symposia and short courses, published more than 30 research articles and book chapters, and made more than 150 presentations at industry and academic meetings. Çelik acted a consultant to FDA and roughly 45 pharmaceutical, nutraceutical, excipient, equipment companies, and law firms worldwide. He currently serves as a member of the editorial board or a reviewer for a numerous pharmaceutical journals. He is the past chair of the American Association of Pharmaceutical Scientists (AAPS) Process Development Focus Group and the founder and the past chair of the AAPS Excipients Focus Group.

Çelik's recent areas of interests include: process analytical technology; development of pharmaceutical expert systems, excipient databases, and management tools in the area of drug delivery technologies; use of compaction simulators in the preformulation and formulation of solid dosage forms; theory and practice of pharmaceutical compaction; excipient functionality testing; and pharmaceutical processing (including milling, mixing, granulation, tableting, and coating).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here